Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Donna Masterman et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Douglas L. Arnold, Shibeshih Belachew et al.|Brain|2019Cited by 217
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesionsColm Elliott, Douglas L. Arnold, Jerry S. Wolinsky et al.|Multiple Sclerosis Journal|2018Cited by 216
Five years of ocrelizumab in relapsing multiple sclerosisStephen L. Hauser, Xavier Montalbán, Ludwig Kappos et al.|Neurology|2020Cited by 159